Table 1 Characteristics of patients selected for the study

From: Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort

 

Population 1a

Population 2b

 

n = 16,701

n = 4033

Characteristics at breast cancer diagnosis

Age at breast cancer diagnosis, median (range), years

54.7 (19.2–98.5)

51.6, 20.3–90.5

Gender

 Female

16 552 (99.1%)

4 007 (99.4%)

 Male

149 (0.9%)

26 (0.6%)

Tumour size

n = 7646

n = 1969

 Tx/T0/Tis

363 (4.7%)

100 (5.1%)

 T1/T2

4 229 (55.3%)

1 044 (53.0%)

 T3/T4

3 054 (39.9%)

825 (41.9%)

Node status

n = 7324

n = 1901

 Nx

318 (4.3%)

77 (4.1%)

 N0

3169 (43.3%)

744 (39.1%)

 N1/N2/N3

3837 (52.4%)

1080 (56.8%)

Metastatic status

n = 16,701

n = 16,701

 M0

11,901 (71.3%)

2974 (73.7%)

 M1

4800 (28.7%)

1059 (26.3%)

Histology

n = 15,584

n = 3790

 Ductal carcinoma

12 537 (80.4%)

3 222 (85.0%)

 Lobular carcinoma

2 187 (14.0%)

395 (10.4%)

 Other

860 (5.5%)

173 (4.6%)

SBR grade

n = 14,779

n = 3652

 I/II

8308 (56.2%)

1641 (44.9%)

 III

6471 (43.8%)

2011 (55.1%)

ER status

n = 15,494

n = 3800

 Negative

3834 (24.7%)

1506 (39.6%)

 Positive

11,660 (75.3%)

2294 (60.4%)

PR status

n = 14,990

n = 3682

 Negative

6375 (42.5%)

2075 (56.4%)

 Positive

8615 (57.5%)

1607 (43.6%)

HER2 status

n = 13,621

n = 3488

 Negative

11,090 (81.4%)

2481 (71.1%)

 Positive

2531 (18.6%)

1007 (28.9%)

Tumour biology

n = 13,498

n = 3453

 HER2−/HR+

8654 (64.1%)

1572 (45.5%)

 HER2+/HR+

1480 (11.0%)

504 (14.6%)

 HER2−/HR+

1010 (7.5%)

490 (14.2%)

 Triple negative

2354 (17.4%)

887 (25.7%)

Radiotherapy delivered on the breast

n = 16,654

n = 4023

 Yes

10,463 (62.8%)

2668 (66.3%)

Systemic treatment

n = 16,657

n = 4026

 Yes

8498 (51.0%)

2463 (61.2%)

Trastuzumab (HER2+ patients)

n = 2531

n = 1007

 Yes

947 (37.4%)

472 (46.9%)

Hormone therapy (HR+ patients)

n = 11,947

n = 2375

 

7354 (61.6%)

1541 (64.9%)

Characteristics at metastatic disease diagnosis

  

Age at MBC diagnosis, median (range), years

61.2 (19.2–99.4)

56.0 (22.0–91.0)

Time interval from breast cancer diagnosis, median (range), months

35.7 (0.0–657.7)

27.3 (0.0–591.7)

Time interval from breast cancer diagnosis

n = 16,656

n = 4026

  < 6 months

4763 (28.6%)

1053 (26.2%)

 6–24 months

2185 (13.1%)

789 (19.6%)

 ≥ 24 months

9708 (58.3%)

2184 (54.2%)

ER statusc

n = 16,100

n = 3906

 Positive

11,924 (74.1%)

2292 (58.7%)

PR statusc

n = 15,702

n = 3815

 Positive

8308 (52.9%)

1515 (39.7%)

HER2 statusc

n = 14,938

n = 3707

 Positive

2719 (18.2%)

1066 (28.8%)

Tumour biology

n = 15,004

n = 3708

 HER2−/HR+

9533 (63.5%)

1667 (45.0%)

 HER2+/HR+

1652 (11.0%)

534 (14.4%)

 HER2+/HR−

1168 (7.8%)

557 (15.0%)

 Triple negative

2651 (17.7%)

950 (25.6%)

Number of metastatic sites

Median (range)

1 (0–9)

–

CNS metastases

n = 16,065

–

 

1200 (7.5%)

Bone metastases

n = 16,067

–

 

9512 (59.2%)

Lung metastases

n = 16,065

–

 

4103 (25.3%)

Liver metastases

n = 16,060

–

 

4491 (28.0%)

Lymph node metastases

n = 16,066

–

 

4478 (27.9%)

Subcutaneous metastases

n = 16,065

–

 

1834 (11.4%)

Pleural metastases

n = 16,067

–

 

1789 (11.1%)

Metastases of other site(s)

n = 16,068

–

 

1727 (10.7%)

  1. SBR grade Scarff–Bloom–Richardson grade, ER oestrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, MBC metastatic breast cancer, CNS central nervous system
  2. aPopulation 1 corresponds to the overall ESME population
  3. bPopulation 2 corresponds to patients diagnosed with CNS metastases before the closing date of the study analyses (January 15th, 2016)
  4. cER, PR and HER2 statuses at MBC diagnosis are defined as follows: status at the metastatic disease diagnosis, if available, or status of the primary tumour
Back to article page